A phase I study of novel dual Bcl-2/Bcl-xL inhibitor APG-1252 in patients with advanced small cell lung cancer (SCLC) or other solid tumor.

被引：3
|
作者：
Lakhani, Nehal J.
Rasco, Drew W.
Tolcher, Anthony W.
Huang, Yingjie
Ji, Jiao
Wang, Hengbang
Dong, Qi
Men, Lichuang
O'Rourke, Timothy J.
Chandana, Sreenivasa R.
Amaya, Alex
Cole, Yvette
Kaiser, Brianne
Mays, Theresa A.
Patnaik, Amita
Papadopoulos, Kyriakos P.
Yang, Dajun
Zhai, Yifan
机构：
[1] START Midwest, Grand Rapids, MI USA
[2] South Texas Accelerated Res Therapeut, San Antonio, TX USA
[3] Ascentage Pharma Grp Inc, Rockville, MD USA
[4] Suzhou Ascentage Pharma Inc, Suzhou, Peoples R China
[5] Suzhou Ascentage Pharma Inc, Suzhou, Peoples R China
[6] Canc & Hem Ctr West Michigan, Grand Rapids, MI USA
[7] Western Michigan Canc Ctr, Kalamazoo, MI USA
[8] START Ctr Canc Care, San Antonio, TX USA
[9] START Midwest Canc Hematol Centers Western Michig, Grand Rapids, MI USA
[10] South Texas Accelerated Res Therapeut START Ctr C, San Antonio, TX USA
[11] START, San Antonio, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.2594
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2594
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A Phase I Study of Novel Bcl-2/Bcl-xL Inhibitor APG-1252 in Patients with Advanced SCLC or Other Solid Tumor
    Wu, Y.
    Lakhani, N. J.
    Boyer, M.
    Zhou, Q.
    Rasco, D. W.
    Huang, Y.
    Men, L.
    Li, Y.
    Xia, Z.
    Wang, H.
    Ji, J.
    Lu, B.
    He, Z.
    Dong, Q.
    Yang, D.
    Zhai, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) : S1048 - S1049
  • [2] Targeting BCL-2 and BCL-xL with a novel dual inhibitor APG-1252 triggers cell death and inhibits tumor growth in small cell lung cancer models
    Wang, GuangFeng
    Min, Ping
    Wu, MiaoYi
    Dang, Shuo
    Tang, ChuanYan
    Zhang, Fei
    Guo, Ming
    Wang, Shaomeng
    Deng, Jing
    Fang, Douglas D.
    Yang, DaJun
    Zhai, YiFan
    CANCER RESEARCH, 2018, 78 (13)
  • [3] BM-1252 (APG-1252): a potent dual specific Bcl-2/Bcl-xL inhibitor that achieves complete tumor regression with minimal platelet toxicity
    Bai, L.
    Chen, J.
    Liu, L.
    McEachern, D.
    Aguilar, A.
    Zhou, H.
    Yang, C. Y.
    Wang, H.
    Wen, J.
    Wang, G.
    Zhai, Y.
    Guo, M.
    Yang, D.
    Wang, S.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 109 - 110
  • [4] Therapeutic potential of the novel Bcl-2/Bcl-XL dual inhibitor, APG1252, alone or in combination against non-small cell lung cancer
    Qian, Luxi
    Vallega, Karin A.
    Yao, Weilong
    Wang, Dongsheng
    Zhai, Yifan
    He, Xia
    Sun, Shi-Yong
    MOLECULAR CARCINOGENESIS, 2022, 61 (11) : 1031 - 1042
  • [5] Dual BCL-2/BCL-XL Inhibitor Pelcitoclax (APG-1252) Overcomes Intrinsic and Acquired Resistance to Venetoclax in Multiple Myeloma Cells
    Yamamoto, Leona
    Derebail, Sanika
    Aktas-Samur, Anil
    Hideshima, Teru
    Chyra, Zuzana
    Chakraborty, Chandraditya
    Yao, Yao
    Gramegna, Doriana
    Morelli, Eugenio
    Samur, Mehmet K.
    Deng, Jing
    Zhai, Yifan
    Gulla, Annamaria
    Fulciniti, Mariateresa
    Anderson, Kenneth C.
    Munshi, Nikhil C.
    BLOOD, 2021, 138
  • [6] Preclinical studies of a dual Bcl-2/Bcl-xL inhibitor APG-1252 with strong anti-tumor efficacy and significantly reduced platelet toxicity
    Wang, H.
    Wang, G.
    Du, Z.
    Wu, M.
    McEachern, D.
    Aguilar, A.
    Lin, Y.
    Lin, X.
    Wen, J.
    Gu, L.
    Guo, M. I. N. G.
    Zhai, Y.
    Wang, S.
    Yang, D.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 176 - 177
  • [7] Antitumor Activity of Dual BCL-2/BCL-Xl Inhibitor Pelcitoclax (APG-1252) in Natural Killer/T-Cell Lymphoma (NK/TCL)
    Wang, Guangfeng
    Liang, Eric
    Ming, Ping
    Rui, Li
    Tang, Chunyang
    Lv, Jing
    Ge, Yangfeng
    Zhang, Fei
    Wang, Lvcheng
    Shang, Jingjin
    Yang, Dajun
    Zhai, Yifan
    BLOOD, 2021, 138
  • [8] Combination of BCL-2/BCL-xL dual inhibitor APG-1252 and chemotherapeutics overcomes resistance to osimertinib in EGFR mutant NSCLC in preclinical models
    Tao, Ran
    Wang, Guangfeng
    Fang, Douglas D.
    Zhai, Guoqin
    Li, Yuanbao
    Lv, Jing
    Wu, Miaoyi
    Ge, Yangfeng
    Zhang, Feifei
    Wen, Danyi
    Yang, Dajun
    Zhai, Yifan
    CANCER RESEARCH, 2020, 80 (16)
  • [9] Trial in Progress: Phase Ib/II Study of Bcl-2/Bcl-Xl Inhibitor Pelcitoclax (APG-1252) in Patients with Myelofibrosis (MF) That Progressed after Initial Therapy
    Pemmaraju, Naveen
    Mudenda, Boyd
    Wang, Cunlin
    Ji, Jiao
    Lu, Ming
    Fu, Tommy
    Liang, Eric
    McClain, Sasha
    Sheladia, Piyush
    Verstovsek, Srdan
    Yang, Dajun
    Zhai, Yifan
    BLOOD, 2020, 136
  • [10] A novel Bcl-2/Bcl-XL inhibitor APG-1252-12A as a potential therapeutic strategy for gastric carcinoma
    Yan, Xianglei
    Yi, Hanjie
    Luo, Qiuyun
    Yuan, Luping
    Zhou, Suna
    Pan, Wentao
    Zhang, Lin
    Qiu, Miaozhen
    Yang, Dajun
    CANCER RESEARCH, 2019, 79 (13)
12345